Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery

Not Applicable

Completed

Conditions: Stage III Prostate Cancer AJCC v7
Prostate Adenocarcinoma
Stage IIB Prostate Cancer AJCC v7
Stage IV Prostate Cancer AJCC v7

Interventions: Procedure: Computed Tomography
Radiation: Gallium Ga 68 Gozetotide
Procedure: Positron Emission Tomography

First Posted Date: 2017-12-11

Last Posted Date: 2023-04-12

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 400

Registration Number: NCT03368547

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors

Not Applicable

Completed

Conditions: Stage II Breast Cancer AJCC v6 and v7
Cancer Survivor
Stage I Breast Cancer AJCC v7
Stage IA Breast Cancer AJCC v7
Stage 0 Breast Cancer AJCC v6 and v7
Stage IIB Breast Cancer AJCC v6 and v7
Stage IIIA Breast Cancer AJCC v7
Stage IB Breast Cancer AJCC v7
Stage IIA Breast Cancer AJCC v6 and v7

Interventions: Behavioral: Behavioral Intervention
Other: Questionnaire Administration

First Posted Date: 2017-10-24

Last Posted Date: 2020-07-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 133

Registration Number: NCT03319342

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of California-Riverside, Riverside, California, United States

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Phase 1

Terminated

Conditions: HLA-A*0201 Positive Cells Present
Sarcoma
Unresectable Malignant Neoplasm
Locally Advanced Malignant Neoplasm
NY-ESO-1 Positive

Interventions: Other: 18F-FHBG
Biological: Aldesleukin
Drug: Busulfan
Biological: Cellular Therapy
Procedure: Computed Tomography
Biological: Filgrastim
Drug: Fludarabine
Procedure: Leukapheresis
Drug: Plerixafor
Procedure: Positron Emission Tomography

First Posted Date: 2017-08-07

Last Posted Date: 2023-11-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 5

Registration Number: NCT03240861

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery

Not Applicable

Completed

Conditions: Lesion
Breast Neoplasm

Interventions: Device: Implanted Medical Device
Procedure: Mammography
Other: Questionnaire Administration
Procedure: Radiofrequency (RFID) -Guided Localization
Procedure: Ultrasonography

First Posted Date: 2017-06-28

Last Posted Date: 2020-07-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 50

Registration Number: NCT03202472

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

Phase 1

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Durvalumab (MEDI 4736)
Radiation: Radiotherapy

First Posted Date: 2017-05-11

Last Posted Date: 2024-08-23

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT03148327

Locations: 🇦🇺
Peter MacCallum Cancer Centre, Melbourne E., Victoria, Australia
🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States

and more 1 locations

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Phase 1

Terminated

Conditions: Invasive Breast Carcinoma
Stage II Breast Cancer
Stage IIA Breast Cancer
Estrogen Receptor Positive
HER2/Neu Negative
Multifocal Breast Carcinoma
Postmenopausal
Progesterone Receptor Positive
Stage I Breast Cancer
Stage IA Breast Cancer

Interventions: Drug: Copanlisib
Procedure: Biopsy of Breast
Other: Laboratory Biomarker Analysis
Drug: Letrozole
Other: Pharmacological Study
Drug: Palbociclib

First Posted Date: 2017-04-25

Last Posted Date: 2022-09-26

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 10

Registration Number: NCT03128619

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma

Conditions: Ewing Sarcoma

First Posted Date: 2017-01-24

Last Posted Date: 2019-03-28

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT03029481

Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)

Not Applicable

Conditions: Stage IIIB Breast Cancer
Early-Stage Breast Carcinoma
Stage 0 Breast Cancer
Stage IIIC Breast Cancer
Cancer Survivor
Stage IA Breast Cancer
Stage IIIA Breast Cancer
Stage IB Breast Cancer
Stage IIA Breast Cancer
Stage IIB Breast Cancer

Interventions: Other: Educational Intervention
Other: Laboratory Biomarker Analysis
Procedure: Meditation Therapy
Other: Questionnaire Administration

First Posted Date: 2017-01-19

Last Posted Date: 2022-07-21

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 96

Registration Number: NCT03025139

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

Phase 2

Withdrawn

Conditions: Oligodendroglioma
Giant Cell Glioblastoma
Gliosarcoma
Small Cell Glioblastoma
Recurrent Glioblastoma

Interventions: Biological: autologous dendritic cells pulsed with tumor lysate antigen Vaccine
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Biological: Nivolumab
Other: Questionnaire Administration

First Posted Date: 2017-01-09

Last Posted Date: 2020-07-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT03014804

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

Phase 3

Completed

Conditions: Prostate Adenocarcinoma
Recurrent Prostate Carcinoma

Interventions: Radiation: Gallium Ga 68 Gozetotide
Other: Laboratory Biomarker Analysis
Procedure: Positron Emission Tomography

First Posted Date: 2016-10-20

Last Posted Date: 2021-07-02

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1138

Registration Number: NCT02940262

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy